Olanzapine for Nausea After Surgery
Primary Purpose
Postoperative Nausea and Vomiting
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Olanzapine
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Nausea and Vomiting focused on measuring Nausea, Vomiting
Eligibility Criteria
Inclusion Criteria:
- Adults age ≥ 18 and ≤ 50 years old
- Patient scheduled to undergo ambulatory surgery under general anesthesia
- Willing and able to provide informed consent
Exclusion Criteria:
- Unable to swallow pills
- Current use of typical or atypical anti-psychotic medications
- History of allergy to olanzapine
- Pregnancy/Lactation (subjects of child-bearing potential will have a urine pregnancy test performed the day of surgery)
- History of QTc > 450ms or torsades de pointes
- Current use of antihypertensive medication
- Diabetes Mellitus
Clinically significant cardiovascular disease defined as follows:
- Myocardial infarction or unstable angina within 6 months prior to the day of planned surgery.
- History of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication.
- New York Heart Association (NYHA) Class II or higher congestive heart failure.
- Postural hypotension or vasovagal syncope within 6 months of planned surgery.
- Hypotension on day of surgery, defined as a systolic blood pressure < 90mm Hg or a diastolic pressure < 60mm Hg.
- Seizure disorder
- Clinically active prolactinoma
- Hepatic disease
- Poorly controlled diabetes
- Pre-operative blood glucose > 250 mg/dL
- Narrow angle glaucoma
- Parkinson's disease
- Lewy body dementia
Sites / Locations
- Icahn School of Medicine at Mount Sinai
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Olanzapine
Placebo
Arm Description
10mg pill
Outcomes
Primary Outcome Measures
Number of Participants With Nausea and/or Vomiting
Number of participants with post-discharge nausea and/or vomiting
Number of Participants With Severe Nausea
Number of participants with severe postdischarge nausea, defined as numerical rating scale score greater than 3. (11-point numerical rating scale from 0-10, higher score indicating worse nausea)
Secondary Outcome Measures
Number of Participants With Postdischarge Vomiting
Number of participants with post discharge vomiting
Number of Participants With PONV
Number of participants with postoperative nausea and/or vomiting (PONV) in first 24 hours
Number of Participants With Severe PONV
Number of participants with severe PONV in first 24 hours after post-op.defined as numerical rating scale score greater than 3. (11-point numerical rating scale from 0-10, higher score indicating worse nausea)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02755116
Brief Title
Olanzapine for Nausea After Surgery
Official Title
Olanzapine for the Treatment of Post-Discharge Nausea and Vomiting After Ambulatory Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
April 2016 (undefined)
Primary Completion Date
September 5, 2019 (Actual)
Study Completion Date
September 5, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jaime B Hyman
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Ambulatory surgery is occurring with rapidly increasing frequency as surgical and anesthetic techniques have improved and pressure to reduce health-care costs has increased. While there are many benefits to recovering from surgery within the home, a significant disadvantage is the lack of rapid access to a healthcare provider when postoperative complications occur. Postoperative nausea and vomiting (PONV) are common after surgery and anesthesia, and recent studies have demonstrated a high incidence of post-discharge nausea and vomiting (PDNV) after ambulatory surgery, particularly in high-risk groups (female gender, age less than 50 years, history of PONV, opioid administration in the post-anesthesia care unit (PACU), and nausea in the PACU). Current practices known to reduce the risk of postoperative nausea and vomiting in the PACU, such as the avoidance of volatile anesthetics and the use of intraoperative ondansetron and steroids, have little effect on the risk of delayed PDNV. Novel strategies to prevent PDNV are needed. Orally administered olanzapine, which has been shown to decrease the incidence of chemotherapy-induced nausea and vomiting, demonstrates promise as a novel strategy for preventing PDNV. It has a long half-life, allowing for a single dose to be administered preoperatively. This study will evaluate whether there is a difference in the incidence and severity of PDNV between patients who receive oral olanzapine versus placebo prior to general anesthesia for ambulatory surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Nausea and Vomiting
Keywords
Nausea, Vomiting
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Olanzapine
Arm Type
Experimental
Arm Description
10mg pill
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Olanzapine
Other Intervention Name(s)
Zyprexa, 132539-06-1, Zyprexa Zydis, Olansek, Symbyax2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Intervention Description
10mg of olanzapine by mouth prior to anesthetic induction
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo by mouth prior to anesthetic induction
Primary Outcome Measure Information:
Title
Number of Participants With Nausea and/or Vomiting
Description
Number of participants with post-discharge nausea and/or vomiting
Time Frame
in 24 hours after discharge
Title
Number of Participants With Severe Nausea
Description
Number of participants with severe postdischarge nausea, defined as numerical rating scale score greater than 3. (11-point numerical rating scale from 0-10, higher score indicating worse nausea)
Time Frame
in 24 hours after discharge
Secondary Outcome Measure Information:
Title
Number of Participants With Postdischarge Vomiting
Description
Number of participants with post discharge vomiting
Time Frame
in 24 hours after discharge
Title
Number of Participants With PONV
Description
Number of participants with postoperative nausea and/or vomiting (PONV) in first 24 hours
Time Frame
first 24 hours post-op
Title
Number of Participants With Severe PONV
Description
Number of participants with severe PONV in first 24 hours after post-op.defined as numerical rating scale score greater than 3. (11-point numerical rating scale from 0-10, higher score indicating worse nausea)
Time Frame
first 24 hours post-op
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults age ≥ 18 and ≤ 50 years old
Patient scheduled to undergo ambulatory surgery under general anesthesia
Willing and able to provide informed consent
Exclusion Criteria:
Unable to swallow pills
Current use of typical or atypical anti-psychotic medications
History of allergy to olanzapine
Pregnancy/Lactation (subjects of child-bearing potential will have a urine pregnancy test performed the day of surgery)
History of QTc > 450ms or torsades de pointes
Current use of antihypertensive medication
Diabetes Mellitus
Clinically significant cardiovascular disease defined as follows:
Myocardial infarction or unstable angina within 6 months prior to the day of planned surgery.
History of serious ventricular arrhythmia (i.e.: ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications, except for atrial fibrillation that is well controlled on anti-arrhythmic medication.
New York Heart Association (NYHA) Class II or higher congestive heart failure.
Postural hypotension or vasovagal syncope within 6 months of planned surgery.
Hypotension on day of surgery, defined as a systolic blood pressure < 90mm Hg or a diastolic pressure < 60mm Hg.
Seizure disorder
Clinically active prolactinoma
Hepatic disease
Poorly controlled diabetes
Pre-operative blood glucose > 250 mg/dL
Narrow angle glaucoma
Parkinson's disease
Lewy body dementia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jaime B Hyman, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Icahn School of Medicine at Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22846680
Citation
Apfel CC, Philip BK, Cakmakkaya OS, Shilling A, Shi YY, Leslie JB, Allard M, Turan A, Windle P, Odom-Forren J, Hooper VD, Radke OC, Ruiz J, Kovac A. Who is at risk for postdischarge nausea and vomiting after ambulatory surgery? Anesthesiology. 2012 Sep;117(3):475-86. doi: 10.1097/ALN.0b013e318267ef31.
Results Reference
background
PubMed Identifier
32229754
Citation
Hyman JB, Park C, Lin HM, Cole B, Rosen L, Fenske SS, Barr Grzesh RL, Blank SV, Polsky SB, Hartnett M, Taub PJ, Palvia V, DeMaria S Jr, Ascher-Walsh C. Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial. Anesthesiology. 2020 Jun;132(6):1419-1428. doi: 10.1097/ALN.0000000000003286. Erratum In: Anesthesiology. 2020 Jun 5;:
Results Reference
result
Learn more about this trial
Olanzapine for Nausea After Surgery
We'll reach out to this number within 24 hrs